Hedge Fund MSMB Offers to Buy AMAG For $381M and Thwart Proposed Allos Merger
This article was originally published in The Pink Sheet Daily
Executive Summary
The $18-per-share offer represents a 25% premium over AMAG's stock price as of Aug. 2, but it's not enough to return the anemia drug maker's valuation to the days just before it unveiled the Allos deal on July 20.
You may also be interested in...
Shkreli’s Retrophin Gets Another Injection Of Capital; Talks Up Clinical Plans
The biotech, founded in late 2011 by venture capitalist Martin Shkreli, has yet to make any significant clinical moves with the compounds in its pipeline, but signs show that could change before year-end.
Shareholder Revolt at AMAG Squelches All-Stock Merger with Equally Struggling Allos
AMAG shareholders have killed plans for what they considered an ill-conceived merger and one shareholder calls the vote a "clear signal" that current management isn't fit to run the company.
Shareholder Revolt at AMAG Squelches All-Stock Merger with Equally Struggling Allos
AMAG shareholders have killed plans for what they considered an ill-conceived merger and one shareholder calls the vote a "clear signal" that current management isn't fit to run the company.